In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy
Frontiers in Microbiology · 15.03.2024 · 15
DOI: 10.3389/fmicb.2024.1344962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 15.03.2024. Verfasst von Prasanth Manohar und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, India. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS.
Abstract (Originalsprache)
Infections caused by Pseudomonas aeruginosa are becoming increasingly difficult to treat due to the emergence of strains that have acquired multidrug resistance. Therefore, phage therapy has gained attention as an alternative to the treatment of pseudomonal infections. Phages are not only bactericidal but occasionally show activity against biofilm as well. In this study, we describe the Pseudomonas phage Motto, a T1-like phage that can clear P. aeruginosa infections in an animal model and also exhibits biofilm-degrading properties. The phage has a substantial anti-biofilm activity against strong biofilm-producing isolates ( n = 10), with at least a twofold reduction within 24 h. To demonstrate the safety of using phage Motto, cytotoxicity studies were conducted with human cell lines (HEK 293 and RAW 264.7 macrophages). Using a previously established in vivo model, we demonstrated the efficacy of Motto in Caenorhabditis elegans, with a 90% survival rate when treated with the phage at a multiplicity of infection of 10.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, India.
- Department of Vaccines and Infection Models, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
- School of Applied Sciences, College of Health, Science and Society, University of the West of England, Bristol, United Kingdom.
- Department of Biotechnology, School of Bioscience, Periyar University, Salem, Tamil Nadu, India.
- Department of Biochemistry, Health and Medical University, Erfurt, Germany.
- Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
Förderung
- NIH HHS
Zitieren
APA
Manohar, P., Loh, B., Turner, D., Tamizhselvi, R., Mathankumar, M., Elangovan, N., Nachimuthu, R., & Leptihn, S. (2024). In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1344962
Vancouver
Manohar P, Loh B, Turner D, Tamizhselvi R, Mathankumar M, Elangovan N, et al. In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy. Frontiers in Microbiology. 2024;15. doi:10.3389/fmicb.2024.1344962
BibTeX
@article{Manohar2024,
author = {Manohar, Prasanth and Loh, Belinda and Turner, Dann and Tamizhselvi, Ramasamy and Mathankumar, Marimuthu and Elangovan, Namasivayam and Nachimuthu, Ramesh and Leptihn, Sebastian},
title = {In vitro and in vivo evaluation of the biofilm-degrading Pseudomonas phage Motto, as a candidate for phage therapy},
journal = {Frontiers in Microbiology},
year = {2024},
volume = {15},
doi = {10.3389/fmicb.2024.1344962}
}
EUVIMED